Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)

Historic EBITDA for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.7 million.

  • Dianthus Therapeutics' EBITDA fell 5006.54% to -$36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.9 million, marking a year-over-year decrease of 9103.86%. This contributed to the annual value of -$84.9 million for FY2024, which is 9588.44% down from last year.
  • Per Dianthus Therapeutics' latest filing, its EBITDA stood at -$36.7 million for Q3 2025, which was down 5006.54% from -$31.8 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' EBITDA registered a high of -$7.0 million during Q1 2023, and its lowest value of -$36.7 million during Q3 2025.
  • In the last 4 years, Dianthus Therapeutics' EBITDA had a median value of -$14.7 million in 2023 and averaged -$18.8 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' EBITDA plummeted by 380.17% in 2023, and later crashed by 17601.79% in 2024.
  • Dianthus Therapeutics' EBITDA (Quarter) stood at -$10.1 million in 2022, then decreased by 3.8% to -$10.5 million in 2023, then plummeted by 176.02% to -$29.0 million in 2024, then fell by 26.49% to -$36.7 million in 2025.
  • Its EBITDA was -$36.7 million in Q3 2025, compared to -$31.8 million in Q2 2025 and -$29.3 million in Q1 2025.